Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
42.93 USD | -3.90% | -5.54% | -41.97% |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- The company has insufficient levels of profitability.
- The company is in debt and has limited leeway for investment
- The company's enterprise value to sales, at 3.41 times its current sales, is high.
- The company is highly valued given the cash flows generated by its activity.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-41.97% | 7.92B | A- | ||
+5.99% | 3.51B | C | ||
-4.31% | 2.18B | D+ | ||
-21.69% | 1.97B | - | B- | |
-24.94% | 1.58B | C+ | ||
+31.45% | 1.14B | B- | ||
+26.75% | 792M | C- | ||
-9.83% | 690M | C+ | ||
-26.33% | 532M | C- | ||
+3.38% | 303M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- EXAS Stock
- Ratings Exact Sciences Corporation